New combo therapy takes on bulky tumors
NCT ID NCT06936748
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a new approach for people with large, relapsed solid tumors that have not responded to standard treatments. It combines a special type of radiation (spatially fractionated radiation therapy) with two immunotherapy drugs (iparomlimab and tuvonralimab). The goal is to see if this combination is safe and can shrink tumors or control the disease. The study will enroll 30 participants and will also look for biomarkers that might predict who benefits most.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Iparomlimab and tuvonralimab (immunotherapy drugs) plus spatially fractionated radiation therapy
What this could lead to
If it works, this could offer a new treatment option for people with large, treatment-resistant tumors, potentially shrinking them and slowing disease progression.
What could go wrong
This is an early phase 2 trial with only 30 participants, so results may not apply to everyone. The combination of radiation and immunotherapy can cause significant side effects, and it's not yet known if it will be more effective than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Second Affiliated Hospital of Nanchang University
RECRUITINGNanchang, Jiangxi, 330006, China
Contact Phone: •••-•••-•••• Email: •••••@•••••